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AbstrACt
Objectives In July 2017, UK National Institute for Health 
and Care Excellence (NICE) published a diagnostic 
guidance (DG30) recommending the use of faecal 
immunochemical tests (FITs) for symptomatic patients 
who do not meet the urgent referral pathway for 
suspected colorectal cancer (CRC). We assessed general 
practitioners’ (GP) awareness of DG30 in primary care 
6 months after its publication.
Design and setting Cross-sectional online survey of 
GPs hosted by an English panel of Primary health care 
professionals.
Participants In December 2017, 1024 GPs registered 
on an online panel (M3) based in England took part in an 
online survey.
Outcomes and variables We investigated a number 
of factors including previous experience of using FIT 
and guaiac faecal occult blood tests (FOBTs), the 
number of urgent referrals for CRC that GPs have 
made in the last year and their sociodemographic and 
professional characteristics that could be associated 
with their self-reported awareness of the FIT 
diagnostic guidance.
results Of the 1024 GPs who completed the survey, 
432 (42.2%) were aware of the current recommendation 
but only 102 (10%) had used it to guide their referrals. 
Awareness was lowest in North West England compared 
with London (30.5% vs 44.9%; adjusted OR: 0.55, 
95% CI 0.33 to 0.92). Awareness of the FIT guidance 
was positively associated with test usage after the 
NICE update (adjusted OR: 13.00, 95% CI 6.87 to 24.61) 
and having specialist training (adjusted OR: 1.48, 
95% CI 1.05 to 2.08). The number of urgent referrals, 
the previous use of FOBt, GPs’ age and gender, work 
experience and practice size (both in terms of the 
number of GPs or patients at the practice) were not 
associated with awareness.
Conclusions Less than half of GPs in this survey 
recognised the current guidance on the use of FIT. Self-
reported awareness was not systematically related to 
demographic of professional characteristics.
IntrODuCtIOn   
Although organised colorectal cancer (CRC) 
screening offers the best chance for early 
detection at an asymptomatic stage, it only 
accounts for 10% of all CRC diagnosis. A 
third of the patients who are symptomatic 
are diagnosed through the urgent cancer 
referral route (2-week wait [2WW]) and a 
quarter are diagnosed following an emer-
gency presentation.1 
Currently, the pathways for symptomatic 
patients are outlined in the National Institute 
for Health and Care Excellence’s (NICE) 
Suspected Cancer: Recognition and Referral 
Guideline (NG12).2 In 2015, the CRC guide-
lines were updated to include vague symp-
toms such as weight loss and abdominal 
pain, which aimed to increase the number 
of cancers diagnosed by the fast-tracked 
2WW-pathway.
The 2015 guideline has also recommended 
the use of guaiac-based faecal occult blood 
tests (FOBts) to safety-net patients whose 
symptoms do not warrant an immediate colo-
noscopy investigation. However, clinicians 
have previously criticised FOBt for its low 
accuracy and general practitioners (GPs) 
strengths and limitations of this study
 ► This is the first study to date to report on general 
practitioner (GP) awareness of the new diagnostic 
guidance (DG30) on the use of home-based stool 
testing. 
 ►  The survey benefited from a large national online 
panel of GPs. 
 ►  Only a small proportion of GPs responded to the 
survey potentially undermining the representative-
ness of our findings. 
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were discouraged to use this test to guide their referral 
decisions.3
More recently, there has been increasing evidence for 
promoting the use of quantitative faecal immunochem-
ical tests (FITs) in primary care as a point of care test to 
triage patients that present with symptoms but do not 
meet the 2WW referral criteria.4 5 The primary advan-
tage of FIT for symptomatic patients is its potential to 
reduce the number of unnecessary colonoscopies, thus 
avoiding associated risks from the procedure and free up 
endoscopy capacity that can be reused to carry out proce-
dures for high-risk patients.6–8 There is a growing body of 
evidence that the FIT test with a diagnostic threshold of 
10 µg of haemoglobin per gram of faeces could be used 
to guide GP referral for further investigation for signif-
icant bowel diseases.9–12 Thus, in July 2017, the NICE 
has published a diagnostic guidance (DG30) and subse-
quently updated NG12 to replace the FOBt with a more 
accurate FIT test.13
All NICE guidelines are freely available online. Their 
adoption of primary care is a key challenge to implemen-
tation as they are not mandatory unlike organised cancer 
screening programmes that are implemented nationally. 
A recent Delphi survey on the adoption of NICE recom-
mendations in primary care suggests that while GPs 
agree with the importance and validity of evidence-based 
recommendations, their adoption will depend on the 
brevity of the guidelines, the communication strategies 
to make it accessible and the relevance of the evidence 
to primary care patients.14 Furthermore, their adop-
tion depends on how GPs have been informed about 
the recommendations by the local or national author-
ities.15 16 Another important consideration is whether 
recommendations are being positioned as a guidance or 
as a guideline. According to the NICE website,17 a guide-
line provides recommendations on how care and services 
should be provided for a specific condition ranging from 
provision of clinical guidelines to safe staffing guidelines. 
Conversely, a specific guidance is less binding but aims to 
give evidence-based support to healthcare professionals 
making decisions on the use of specific innovations. NICE 
guidance (NG) includes recommendations on tech-
nology, prescriptions as well as diagnostic technologies 
such as FIT.
Only a handful of studies have investigated the barriers 
and facilitators of the implementation of specific NICE 
recommendations, eg, adoption of the NG12 guideline 
and the clinical guideline for breast cancer (CG164).18–20 
Among those studies, lack of awareness (eg, only 24% of 
GPs participating in an online study were aware of the 
CG164 recommending the use of tamoxifen to women 
with increased risk of breast cancer) was cited as a major 
barrier for GPs to prescribe the drug.19 Low awareness 
could explain why a subsequent prospective study using 
health records showed low adherence to the recommen-
dations for prescribing tamoxifen since 2013.20
Furthermore, a recent study from Denmark reported 
that GPs’ capability of using FIT was limited by their 
awareness of the test kit and perceived lack of support from 
other GPs and practice staff.21 The decision to commis-
sion the use of FIT in symptomatic primary care patients 
is made by local Clinical Commissioning Groups (CCGs). 
While they are national FIT guidelines, each CCG has 
the autonomy to respond in the most appropriate way to 
meet local requirements. At the time of the survey, there 
were clear examples of how CCGs had responded to the 
NG12 FIT guidance in the adoption resource published 
with the DG30 guidance.13 For example, in Oxfordshire a 
series of outreach educational sessions were delivered by 
the CCG accompanied by email educational bulletins to 
all GPs and information posted on the Oxford University 
Hospitals laboratory webpages.
Thus, the present study aimed to assess GPs’ self-re-
ported awareness of the FIT recommendation across 
England for patients who do not meet the 2WW criteria 
since DG30 was published in July 2017.
MethODs
study design and population
The data were collected as part of a 10 min online survey 
in December 2017 that aimed to investigate GPs’ accept-
ability of FIT in primary care as a rule-out test of CRC 
among symptomatic patients.22 14 100 GPs from England 
were invited to take part via email using M3 Global 
Research’s panel of 41 935 GPs and health professionals 
in England.
GPs were eligible if they were working in England at 
the time of the study. Once they agreed to take part, they 
were provided with information on the current NICE 
guidelines and the DG30 update as part of the informa-
tion provided on FIT as a rule-out test (see online supple-
mentary materials).
Duplicates and incomplete data were excluded from 
the final analysis. The survey was hosted by an online 
cloud-based survey administration company called 
Survey Monkey Limited and the order of the questions 
was randomised. Only researchers at University College 
London (UCL) had access to the data. GPs were offered 
an industry standard honorarium.
Patient and public involvement
This work forms part of the University College London 
Hospita (UCLH) Cancer Collaborative whose overall 
strategy is informed through consultation with patient 
representatives. As the main topic of this survey was 
directed at healthcare professionals and their decision 
making its development was informed by previous inter-
views and consultation with GPs, particularly with one of 
our coauthors (BDN).
Measures
Self-reported awareness of the diagnostic guidance 
recommendation on using FIT (DG30)
After having been presented with information about 
current recommendation, respondents were asked 
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whether they recognised guidance on the use of FIT as a 
triage test for low-risk patients who do not meet the 2WW 
criteria based on DG30
(“Before today, were you aware that FIT can be used in primary 
care to rule in [detect] colorectal cancer among patients with 
colorectal cancer symptoms among low risk patients?”).
GPs’ demographic and professional characteristics
GPs were asked to provide their age range, gender, years 
of experience as an active GP and role in their practice. 
GPs were also asked to provide details of the region in 
England where they are based.
A recent study on the implementation of NICE recom-
mendations in healthcare settings suggests involve-
ment in budget setting and clinical engagement are 
important facilitators of adoption of new guidelines.23 
Thus, we additionally asked GPs about their engagement 
in implementation/budget planning, role as a cancer 
lead, engagement in research, the number of registered 
patients and the number of GPs working in their practice.
GPs were also asked to indicate if they had received 
specialist training. A summary of respondents’ special-
isms is listed in the online supplementary materials. For 
the purpose of the analysis, we dichotomised respondents 
as those who did or did not receive specialist training.
Previous experience using faecal tests
Previous experience of requesting FOBt and FIT for symp-
tomatic patients based on the NICE Guideline (NG12) 
or recent diagnostic guidance (DG30) was assessed using 
dichotomous (Yes/No) items.
Number of 2WW referrals for suspected CRC in the last 12 months
We asked GPs to indicate the number of 2WW referrals 
they had made over the past 12 months.
statistical analysis
Simple logistic regression analyses were used to look at 
bivariate and multivariate associations between awareness 
of diagnostic guidance (DG30) and GPs demographic 
and professional characteristics, previous use of faecal 
tests for symptomatic patients and also the number of 
2WW referrals they had personally made in the last year. 
The results were reported using percentages, unadjusted 
ORs, adjusted ORs (aORs) and 95% CIs. All analyses were 
completed using SPSS V.23.
results
Population characteristics
The sample characteristics have been reported previously 
(22). In brief, just under 10% of the GPs responded to 
the invitation to the online survey (n=1351). Of the 1351 
GPs, 24.2% of the initial respondents either dropped 
out of the survey during data collection (n=209) or were 
excluded because they did not qualify or had already 
completed survey previously (n=118). In total, 1024 GPs 
from England successfully completed the survey.
self-reported awareness of FIt diagnostic guidance for 
symptomatic low-risk patients
42.2% (n=432) of respondents were aware of the use of 
FIT as a triage test for low-risk patients based on DG30. 
About half of the respondents (54.4%, n=558) stated that 
they used FOBt for low-risk patients according to NG12 
published in 2015 and only about 10% (n=102) used FIT 
since it was updated in July 2017 following the publication 
of DG30.
Table 1 shows the unadjusted and adjusted regression 
analysis. Respondents were significantly more likely to be 
aware of the FIT recommendation if they had requested 
low-risk patients to complete FIT since July 2017 compared 
with those who had not (88.2% vs 37.1%; aOR 13.00, 95% 
CI 6.87 to 24.61). GPs with any specialist training were 
more likely to be aware of the FIT recommendation for 
low-risk patients compared with those who had not received 
specialist training (50.5% vs 39.9%; aOR 1.48, 95% CI 1.05 
to 2.08). Respondents were less likely to be aware of the 
FIT recommendation if they were working in North West 
England compared with London (30.5% vs 44.9%; aOR 
0.55, 95% CI 0.33 to 0.92). There were no differences in 
respondents’ awareness of the FIT recommendation by 
GPs age, gender and employment status, number of years 
working as a GP and having a role in budget setting.
DIsCussIOn
This survey provides insights about GPs’ awareness of the 
latest FIT recommendations in the National Guideline 
for Suspected Cancer: Recognition and Referral. Even 
though 42% of participants being aware of DG 30 was 
higher than what has been cited for other clinical guide-
lines (eg, CG164),19 our findings suggest that awareness 
of the diagnostic guidance approximately 6 months after 
their publication is still relatively low and geographically 
varied. In particular, GPs who took part in this study were 
less likely to be aware of the update, if they were based in 
the North West of England.
As it stands, the evidence on GP awareness and the adop-
tion of NICE guidelines for suspected CRC is scarce. The 
International Cancer Benchmarking Partnership study 
on adherence to national guidelines suggest that less than 
half of GPs in the UK adhere to the CRC referral guide-
lines and the majority will ignore the guidelines if they 
see a patient with symptoms suggestive of CRC.18 This was 
further supported in recent papers that GPs are currently 
more inclined to use 2WW referrals to rule out CRC, 
and they perceive safety netting in cancer diagnosis (eg, 
watchful waiting and telling patients to come back if the 
symptoms persist) to be ineffective and potentially leading 
to diagnostic delays.6 23 It is not clear to what extent FIT 
can address these concerns particularly as FIT bears a 
close family resemblance to the FOBt which is used in the 
asymptomatic population and often viewed critically by the 
primary care community due to its low sensitivity.3 23
Furthermore, the outcomes of this study provide the 
baseline and an early indication for the adoption of the 
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Table 1 Unadjusted and adjusted logistic regression models
% (n) FIT Awareness
Unadjusted Adjusted
OR (95% CI) OR (95% CI)
Overall 42.2 (432)
Age 
  35 or under 39.6 (89) 1 1
  36–45 44.2 (200) 1.21 (0.87 to 1.67) 1.11 (0.74 to 1.66)
  46–55 41.0 (89) 1.06 (0.73 to 1.55) 0.99 (0.57 to 1.68)
  56 or older 41.9 (54) 1.10 (0.71 to 1.71) 0.82 (0.44 to 1.53)
Gender 
  Male 43.1 (235) 1 1
  Female 41.1 (197) 0.92 (0.72 to 1.18) 0.90 (0.67 to 1.21)
Employment 
  Trainee 37.5 (15) 1 1
  Full time 42.4 (120) 1.23 (0.62 to 2.43) 0.94 (0.43 to 2.08)
  Part time 43.0 (114) 1.26 (0.63 to 2.49) 1.19 (0.55 to 2.55)
  Locum 42.3 (69) 1.22 (0.60 to 2.49) 1.10 (0.49 to 2.45)
  Partner 41.0 (107) 1.16 (0.58 to 2.30) 1.01 (40.45 to 2.23)
  Other 58.3 (7) 2.33 (0.63 to 8.68) 2.46 (0.59 to 10.32)
Years active as a GP 
  Less than 10 years 40.9 (195) 1 1
  More than 10 years 43.3 (237) 1.11 (0.86 to 1.42) 1.03 (0.71 to 1.49)
Have a role in budget setting 
  No 41.2 (324) 1 1
  Yes 45.6 (108) 1.19 (0.89 to 1.60) 1.03 (0.72 to 1.46)
Have a specialism* 
  No 39.9 (320) 1 1
  Yes 50.5 (112) 1.53 (1.14 to 2.07) 1.48 (1.05 to 2.08)
Actively involved in research 
  No 41.0 (365) 1 1
  Yes 50.4 (67) 1.46 (1.02 to 2.11) 1.23 (0.81 to 1.85)
Number of patients registered at their practice 
  Up to 5000 41.8 (69) 1 1
  Between 5000 and 10 000 43.2 (172) 1.06 (0.73 to 1.53) 1.01 (0.65 to 1.56)
  More than 10 000 41.4 (191) 0.98 (0.68 to 1.41) 0.99 (0.59 to 1.56)
Number GPs working in the practice 
  Less than 5 42.8 (131) 1 1
  Between 5 and 10 42.4 (236) 0.98 (0.74 to 1.30) 1.04 (0.71 to 1.53)
  More than 10 15.0 (65) 0.91 (0.62 to 1.33) 1.10 (0.64 to 1.87)
Number of CRC 2 Week Wait referrals in the last year 
  Less than 5 47.1 (72) 1 1
  Between 5 and 10 41.1 (181) 0.78 (0.54 to 1.14) 0.76 (0.51 to 1.13)
  More than 10 41.5 (179) 0.79 (0.55 to 1.16) 0.77 (0.52 to 1.16)
Region in England 
  London 44.9 (88) 1 1
  West Midlands 46.1 (47) 1.05 (0.65 to 1.69) 1.31 (0.79 to 2.17)
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new diagnostic guidance on FIT. From it, there is no clear 
profile emerging as early adopters other than, geograph-
ical location and having received additional specialist 
training.
One explanation of GPs’ low awareness of the guidance 
may relate to the existing low access to faecal occult blood 
tests (~54%) compared with other direct laboratory tests 
provided in primary care such as Ca125 which had 100% 
access across England.24
Furthermore, a recent study on the implementation of 
evidence-based guidelines suggests that current imple-
mentation strategies adopt a top-down approach which 
often lacks sufficient clarity and fails to address local 
circumstances.25 This may also particularly apply to DG30 
because most evidence was collected through secondary 
care and informed by patients who had already been 
referred to 2WW referrals investigations and evidence 
did not to consider the use of FIT as a stand-alone test 
without the added reassurance of a colonoscopy.4
Currently, the small number of local FIT initiatives 
since July 2017 suggest that there might be important 
variation in access to FIT in primary care.26 Low aware-
ness of GPs is therefore likely to reflect macro-level varia-
tion in local commissioning authorities acting on the new 
diagnostic guidance on how to use FIT (DG30). However, 
it was noteworthy that even in areas where FIT has been 
implemented (eg, Oxfordshire, South-West England) 
awareness remained suboptimal (38%).
According to the NICE adoption support guidance 
published in January 2018,26 key stakeholders including 
CCGss, clinicians, laboratories, GPs and local trusts 
should ensure that there is sufficient local preparation. 
Most important here would be to develop standard oper-
ating procedures detailing safety-netting procedures 
for patients who do not return test kits. In addition, it 
is important to develop pathways to follow-up FIT results 
with the appropriate safety netting to ensure patients with 
normal and abnormal follow-up clinical advice.
Importantly, local guideline development should 
involve active participation from local GPs and best 
practice examples using local pilot sites to enhance 
engagement with the guidelines.15 Given that awareness 
is currently low, there is a need to monitor progress in 
improved recognition and adoption. Local commis-
sioners should invest in primary care education and 
training activities as part of the implementation activities. 
Such activities would be particularly important in areas 
with the lowest awareness (eg, North West England).
The primary strength of this study was the use of a very 
large sample of GPs practising in England whose charac-
teristics were very similar to those reported in a previous 
GP-based online survey.18 The primary outcome question 
was embedded in a wider survey on GP acceptability of 
FIT as an alternative to a 2WW referral for patients with 
symptoms suggestive of CRC. As a result, we were limited 
in the scope of questions we could ask about recogni-
tion of the new diagnostic guidance (DG30) and its 
implementation in primary. Future surveys would gain 
deeper insights by addressing additional aspects such as 
GPs’ intended and actual use FIT for low-risk patients, 
the sources where GPs gather and learn new informa-
tion on NG and factors influencing their ability to follow 
guidelines and guidance (eg, implementation by local 
authorities). As this study was cross-sectional, we do not 
know what GPs baseline knowledge of FIT and its role in 
diagnostics was before the introduction of the guideline. 
Future studies using longitudinal data would also enable 
us to disentangle the nature of the relationship between 
awareness and actual FIT use in practice (eg, whether 
awareness prompts FIT use or whether seeking out to use 
% (n) FIT Awareness
Unadjusted Adjusted
OR (95% CI) OR (95% CI)
  South West 37.8 (42) 0.75 (0.46 to 1.20) 0.90 (0.54 to 1.49)
  South East 50.0 (77) 1.23 (0.80 to 1. 87) 1.25 (0.79 to 1.99)
  East of England 47.7 (62) 1.12 (0.80 to 1.87) 1.26 (0.78 to 2.04)
  Yorkshire and the Humber 
and North East
33.3 (38) 0.61 (0.38 to 0.99) 0.75 (0.45 to 1.24)
  North West 30.5 (40) 0.54 (0.34 to 0.86) 0.55 (0.33 to 0.92)
Previous experience using FOBt 
  No 39.9 (186) 1 1
  Yes 44.1 (246) 1.19 (0.93 to 1.52) 0.96 (0.73 to 1.28)
Previous experience using FIT 
  No 37.1 (342) 1 1
  Yes 88.2 (90) 12.72 (6.86 to 23.57) 13.00 (6.87 to 24.61)
The results highlighted in bold indicate p values less than 0.05.
CRC, colorectal cancer; FIT, faecal immunochemical test; GP, general practitioner. 
Table 1 Continued 
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FIT prompts GPs to review clinical referral guidance and 
guidelines). Especially given the low response rate means 
that we cannot exclude the possibility that awareness 
might be lower. Relatedly, we acknowledge that while we 
feel that ORs made our results easier to interpret, their 
values might be inflated compared with risk ratios.
COnClusIOn
Our survey findings suggest that GPs’ awareness of using 
FIT as a triage test in primary care is currently low and 
there is limited insight into the perceived barriers and 
facilitators associated with GPs’ use of the test. Successful 
early adoption of the FIT test in primary care will require 
extensive primary care engagement to raise awareness of 
the NICE guideline and the updated diagnostics guid-
ance in parallel with providing access to the FIT test.
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